Dr. Daniel Haders II is the Co-Founder and CEO of Model Medicines, a generative AI biotechnology company developing first-in-class small-molecule therapeutics. He was recently named one of the Top 50 Healthcare AI Entrepreneurs of 2025 and featured by Bloomberg Intelligence in its Vanguards of Healthcare series. Under his leadership, Model Medicines has been recognized as a Fierce Medtech “Fierce 15” company, one of GEN’s Ten Companies to Watch in AI Drug Discovery, and one of GreyB’s Five Innovative AI Drug Development Startups to Watch in 2025. Previously, Dr. Haders founded and led a digital health accelerator that built a portfolio of 25+ early-stage healthcare companies with top-decile investment performance. As a scientist and pharmaceutical development leader at Lux Biosciences, he advanced LX214 from concept through Phase I; the formulation was later FDA-approved as CEQUA®. He has served as a board member or observer for companies including AppliedVR, Regenexx, and Consano Biologics, and holds academic and advisory roles at UCSD and Columbia University Technology Ventures. Dr. Haders holds a BS from Columbia University and a PhD in Biomedical Engineering from Rutgers University and has authored multiple patents and peer-reviewed publications.